New drug strategy tested to control Tough-to-Treat lung cancer

NCT ID NCT06194448

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a drug called osimertinib as part of a treatment plan for adults with a specific type of advanced, inoperable lung cancer. Participants will take osimertinib for about 8 weeks, then receive standard chemoradiation, and then continue taking osimertinib long-term. The main goal is to see if this approach helps control the cancer and keep it from getting worse for a longer period of time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

Palo Alto, California, 94304, United States
Research Site

Beijing, 100021, China
Research Site

Changsha, 410013, China
Research Site

Guangzhou, 510060, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230001, China
Research Site

Jinan, 250117, China
Research Site

Nanning, 530021, China
Research Site

Shanghai, 200032, China
Research Site

Tianjin, 300060, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430071, China
Research Site

Zhengzhou, 450052, China
Research Site

Haifa, 31096, Israel
Research Site

Jerusalem, 91031, Israel
Research Site

Tel Aviv, 62748, Israel
Research Site

Cheongju-si, 28644, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Suwon, 16247, South Korea
Research Site

Barcelona, 08003, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Granada, 18016, Spain
Research Site

Madrid, 28007, Spain
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Bangkok, 10210, Thailand
Research Site

Bangkok, 10330, Thailand
Research Site

Chiang Rai, 57000, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Ankara, 06010, Turkey (Türkiye)
Research Site

Yenimahalle, 06560, Turkey (Türkiye)
Research Site

Hanoi, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

LUNG CANCER